Welcome to our dedicated page for Viatris SEC filings (Ticker: VTRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Viatris Inc. filings document the reporting record of a global healthcare company whose common stock trades on Nasdaq under VTRS. Form 8-K disclosures cover operating results, guidance and material events, including leadership transitions, restructuring actions from an enterprise-wide strategic review, bylaw amendments and shareholder-meeting matters.
Proxy statements describe board oversight, executive compensation, shareholder voting proposals, director nominations and governance practices. The filings also provide formal records for Viatris' capital return activity, strategic priorities, pipeline and product references, and the company's history as the combination of Mylan with Pfizer's Upjohn business.
Viatris Inc (VTRS) received an amended Schedule 13G/A reporting that FMR LLC and Abigail P. Johnson collectively report beneficial ownership of 126,764,446.45 shares of Viatris common stock, representing 11.0% of the class as of August 31, 2026.
FMR LLC reports sole voting power over 113,359,609.44 shares and sole dispositive power over 126,764,446.45 shares, with no shared voting or dispositive power. Abigail P. Johnson reports sole dispositive power over 126,764,446.45 shares and no voting power. One or more other persons may receive dividends or sale proceeds from these shares, but no such person holds more than five percent of Viatris’s outstanding common stock.
Viatris Inc (VTRS) reported that Chief Administrative and Transformation Officer Andrew Enrietti had restricted stock units (RSUs) and related dividend equivalent units (DEUs) granted on August 15, 2025 vest on August 15, 2026. On that date, 25,134 RSUs and 998.3636 DEUs were converted into common stock. To cover associated tax liabilities on the RSU and DEU settlements, 10,931 and 435 shares of common stock, respectively, were withheld at $16.23 per share. The filing notes that an additional 25,133 RSUs will vest on August 15, 2027 and 25,134 RSUs will vest on August 15, 2028, with DEUs vesting on the same schedule. The Rule 10b5-1 trading plan checkbox was left unchecked.
Davis Selected Advisers reports a significant ownership position in Viatris Inc common stock. The firm is the beneficial owner of 75,232,254 shares, representing 6.5% of the outstanding common stock.
Within this stake, Davis Selected Advisers has sole voting power over 72,567,897 shares, meaning it alone can vote or direct the voting of those shares. It also has sole dispositive power over all 75,232,254 shares, giving it the authority to dispose of or direct the disposition of the entire reported position. No shared voting or shared dispositive power is reported.
The filing identifies Davis Selected Advisers, organized in Colorado and based in Tucson, Arizona, as the reporting person, with the position reported in the common stock of Viatris Inc, CUSIP 92556V106.
Viatris reported Q2 2026 total revenues of $3,756.8 million, up from $3,582.1 million a year earlier, driven by strong brands such as Lipitor ($914.2 million), Norvasc, and other established products. Net sales for the first half of 2026 were $7,255.6 million versus $6,812.2 million in 2025.
The company posted a Q2 2026 net loss of $118.8 million (basic and diluted EPS $(0.10)), but for the first six months generated net earnings of $57.6 million, compared with a net loss of $3,046.6 million in the prior-year period, which had included a $2,936.8 million goodwill impairment. First-half operating cash flow was $770.1 million.
At June 30, 2026, Viatris held $886.5 million in cash and cash equivalents and long-term debt of $11,612.4 million, reflecting repayment of $1.675 billion 2026 Senior Notes and issuance of €650.0 million 4.250% Senior Notes due 2033 plus a new ¥40 billion term loan facility. The company continued returning capital via dividends of $0.12 per share each quarter and repurchased about 9.4 million shares for $150.0 million in the first half, bringing cumulative repurchases under its program to approximately 103.5 million shares for $1.15 billion as of June 30, 2026.
FMR LLC, a Delaware entity, filed as a large shareholder of Viatris Inc. common stock. FMR reports beneficial ownership of 96,362,102.65 shares, representing 8.3% of the outstanding common stock as of the reporting date.
FMR reports sole dispositive powerAbigail P. Johnson is also reported as a beneficial owner with sole dispositive power over the same 96,362,102.65 shares and an 8.3% stake. One or more other persons may have rights to dividends or sale proceeds, but no single other person holds more than five percent of the class.
Viatris Inc. reported second-quarter 2026 total revenues of $3.76 billion, up 5% year over year, and a U.S. GAAP net loss of $118.8 million. The loss was driven largely by a $177.8 million non‑cash charge tied to the planned sale of Tyrvaya product rights.
On a non‑GAAP basis, adjusted net earnings were $808.5 million, adjusted EBITDA was $1.19 billion, and adjusted EPS was $0.69, each rising about 10% or more from the prior‑year quarter. Free cash flow was $329.0 million, nearly doubling from a year earlier, and the gross leverage ratio improved to 2.9x.
Viatris raised the midpoints of its 2026 guidance, now targeting total revenues of about $14.75 billion, adjusted EBITDA of $4.40 billion, adjusted EPS of $2.52, and free cash flow excluding transaction‑related and restructuring‑related costs of $2.20 billion. The company advanced its pipeline with FDA approval of Gwyn Lo and a generic ferric carboxymaltose injection, agreed to sell global Tyrvaya rights for up to $100 million, completed monetization of its Biocon stake, and expects Nashik manufacturing disruptions to reduce second‑half 2026 revenues by $100 million to $150 million while continuing to return capital, including $550 million to shareholders and repayment of $900 million of debt.
SIMMONS DAVID S reported acquisition or exercise transactions in this Form 4 filing.
Viatris Inc director David S. Simmons received a grant of 2,362 deferred stock units (DSUs) on June 30, 2026 as compensation for quarterly non-employee director fees, in lieu of cash. The award was valued using the June 30, 2026 closing price of $15.88 per share of Viatris common stock.
Each DSU is fully vested and represents the right to receive one share of Viatris common stock. The DSUs will be settled in shares upon the earliest of Simmons’ termination of service as a non-employee director, his death or disability, or a change in control of Viatris.
Groothuis Leo Frans reported acquisition or exercise transactions in this Form 4 filing.
Viatris Inc. director Leo Frans Groothuis received a grant of 2,756 deferred stock units (DSUs) on June 30, 2026 as compensation in lieu of cash quarterly non-employee director fees. Each DSU is fully vested and represents one share of Viatris common stock, deliverable upon certain future events such as termination of service or a change in control.
Viatris Inc. has entered into an amended and restated term loan credit agreement providing a senior unsecured term loan facility of ¥40,000,000,000. The company plans to use the funds for general corporate purposes, including repaying its prior ¥40,000,000,000 unsecured term loan facility dated July 1, 2021.
The new Term Loan Credit Facility initially bears interest at the TIBO Rate plus 1.10% per year, with the margin adjustable based on Viatris’ long-term unsecured debt ratings. It includes customary covenants and a financial covenant requiring a leverage ratio no greater than 3.75 to 1.00 at each quarter-end after closing.
The facility is guaranteed by certain subsidiaries and matures three years from the closing date, with amounts voluntarily prepayable at any time without penalty other than customary breakage costs.
Viatris Inc officer Paul Campbell reported selling 50,076 shares of common stock in an open-market transaction at a weighted average price of $16.1711 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 24, 2026, and Campbell now holds 316,212 shares directly plus 318 shares indirectly through a 401(k) plan.